Fluorescent Imaging of Nerves With Illuminare-1 During Surgery

Inclusion Criteria:

18 years or older and capable of signing their own consent form
Scheduled for minimally invasive radical prostatectomy with pelvic lymph node dissection

Exclusion Criteria:

Prior pelvic surgery or pelvic radiation therapy
Known central nervous or peripheral nervous system disease or insult (including neurodegenerative diseases), current use of neurotoxic medications, or use of cytotoxic chemotherapy with known neurotoxicity within 1 month
Exposure to investigational agents in the immediate 30 days before or 15 days after study drug administration
Patients with significant renal dysfunction (<60 mL/min as assessed by the Cockcroft Gault calculation for creatinine clearance)
Clinically significant hepatic/liver impairment (liver function tests more than 2x institutional normal upper limit)
Exposure to phototoxic drugs such as St. John's wort, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulphonamides, quinolones, and tetracyclines, should be avoided. If safe to discontinue use for a limited time, patients may participate on this trial but will discontinue the use of the interfering drug for 5 half-lives before Illuminare-1 injection to permit full washout, as well as for 48 hours after administration of Illuminare-1.